Lipum Q4 report: Focus on clinical progress - Redeye

Redeye provides a research update on Lipum following the Q4 report published by the company earlier today. We make some slight adjustments to our overall estimates following a revision of our model. However, we reiterate our previous fair value range (SEK5 – SEK35) with a base case valuation of SEK22 as we continue to see substantial upside potential in the stock.

Länk till analysen i sin helhet: https://www.redeye.se/research/890807/lipum-q4-report-focus-on-clinical-progress?utm_source=finwire&utm_medium=RSS